Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 32 of 116 for:    medullary carcinoma

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00390325
Recruitment Status : Active, not recruiting
First Posted : October 19, 2006
Results First Posted : December 21, 2018
Last Update Posted : November 26, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally advanced), or has returned after a period of improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Condition or disease Intervention/treatment Phase
Hereditary Thyroid Gland Medullary Carcinoma Multiple Endocrine Neoplasia Type 2A Multiple Endocrine Neoplasia Type 2B Recurrent Thyroid Gland Medullary Carcinoma Stage III Thyroid Gland Medullary Carcinoma AJCC v7 Stage IV Thyroid Gland Medullary Carcinoma AJCC v7 Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7 Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7 Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7 Drug: Sorafenib Drug: Sorafenib Tosylate Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess objective response rate of sorafenib tosylate (sorafenib [BAY 43-9006]) in metastatic medullary thyroid carcinoma in setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma (FMTC).

II. To assess objective response rate of sorafenib (BAY 43-9006) in sporadic metastatic medullary thyroid carcinoma.

SECONDARY OBJECTIVES:

I. To assess toxicity of sorafenib (BAY 43-9006) in patients with metastatic medullary thyroid carcinoma.

II. Measure serum tumor markers calcitonin and carcinoembryonic antigen (CEA) pre-, during, and post-treatment to correlate with disease response.

III. Correlate nuclear medicine functional imaging (fludeoxyglucose F 18 [F-18 fluorodeoxyglucose] positron emission tomography [PET] scan) data obtained at pre-, during, and post-treatment with tumor response.

IV. Correlate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data obtained at pre-, during, and post-treatment with changes in tumor permeability and vascularity with tumor response.

V. Perform pharmacogenomic studies on procured peripheral blood mononuclear cells (PBMCs) if clinical responses are observed.

VI. To correlate between the degree of retrovirus-associated deoxyribonucleic acid (DNA) sequences (Ras)-mitogen-activated protein kinase (MAPK) signaling inhibition with vascular endothelial growth factor (VEGF) expression in the tumor and clinical response.

VII. To correlate between the presence and type of ret proto-oncogene (RET) gene defects in tumor and clinical response.

OUTLINE:

Patients receive sorafenib tosylate orally (PO) twice daily (BID) on days 1-56. Cycles repeats every 8 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 4 weeks.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma
Actual Study Start Date : October 5, 2006
Actual Primary Completion Date : January 30, 2017


Arm Intervention/treatment
Experimental: Treatment (sorafenib tosylate)
Patients receive sorafenib tosylate PO BID on days 1-56. Cycles repeats every 8 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Sorafenib
Given PO
Other Names:
  • BA4 43 9006
  • BAY 43-9006
  • Bay-439006

Drug: Sorafenib Tosylate
Given PO
Other Names:
  • BAY 43-9006 Tosylate
  • BAY 54-9085
  • Nexavar
  • sorafenib




Primary Outcome Measures :
  1. Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Measured using MRI scans. Determined using Response Evaluation Criteria in Solid Tumors/World Health Organization response criteria. 95% confidence interval will be calculated to estimate the frequency of response.


Secondary Outcome Measures :
  1. Number of Patients With Decreased Calcitonin Levels [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Identifying the number of patients with decreased calcitonin levels

  2. Patient With Decreased Carcinoembryonic Antigen (CEA) Levels [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Identify the number of patients with decreased Carcinoembryonic Antigen (CEA) levels

  3. Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep) [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Median decrease in exchange rate Kep in index lesions

  4. Degree of Ras-MAPK Signaling Inhibition in the Tumor [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Identify the number of patients with degree of Ras-MAPK signaling inhibition

  5. Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Correlated with clinical response.

  6. Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET) [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Identify the median SUV at baseline and 8 week follow up as measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET).

  7. Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 [ Time Frame: Up to 4 weeks after last dose of sorafenib tosylate ]
    Toxicities were graded for patients using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0

  8. Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor [ Time Frame: Baseline ]
    Percent of patients with RET mutations

  9. Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity [ Time Frame: Baseline ]
    Changes will be correlated with toxicity and clinical response to therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ELIGIBILITY CRITERIA SPECIFIC FOR ARM A
  • Histologically confirmed medullary thyroid carcinoma under the clinical setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma (FMTC)
  • ELIGIBILITY CRITERIA SPECIFIC FOR ARM B
  • Histologically confirmed medullary thyroid carcinoma under the clinical setting of sporadic medullary thyroid carcinoma (MTC)
  • ELIGIBILITY CRITERIA COMMON FOR ARMS A AND B
  • Patients must have measurable disease
  • Metastatic and/or locally advanced or locally recurrent disease
  • Oral or intravenous (IV) bisphosphonates therapy will be allowed for patients with bony metastasis at the investigator's discretion; bisphosphonate usage should be recorded if used since these agents may have anti-farnesyl transferase activity and may have some therapeutic effect in combination with sorafenib
  • Life expectancy must be >= six months
  • Patients must have an Eastern Cooperative Oncology Group performance status 0-2
  • Leukocytes >= 2,000/uL (10 days prior to patient enrollment)
  • Absolute neutrophil count >= 1,000/uL (10 days prior to patient enrollment)
  • Platelets >= 100,000/uL (10 days prior to patient enrollment)
  • Total bilirubin =< within 2 x upper limit of normal (10 days prior to patient enrollment)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< within 3 x upper limit of normal (10 days prior to patient enrollment)
  • Serum creatinine within normal institutional limits OR creatinine clearance > 30 mL/min (by Cockcroft-Gault formula) (10 days prior to patient enrollment)
  • The effects of sorafenib (BAY 43-9006) on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because kinase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 30 days after completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately (10 days prior to patient enrollment)
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • EXCLUSION CRITERIA FOR ARM A AND B
  • Patients who have had systemic anti-tumor therapy (such as chemotherapy, biologic modifiers or antiangiogenic therapy) within 4 weeks (6 weeks if nitrosourea or mitomycin chemotherapy) prior to study entry
  • Patients who have had external beam radiation therapy within 1 week or if the adverse events associated with radiation are not resolved to grade 1 or less prior to study entry
  • Prior therapy with sorafenib (BAY 43-9006), ZD 6474 or AMG-706
  • Patients currently receiving any other tumor-specific therapy for thyroid cancer or investigational therapy; patients receiving adjuvant hormonal therapy for a second primary (such as breast cancer or prostate cancer) are allowed to participate as far as there are no known drug interactions
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib (BAY 43-9006)
  • Patients unable to swallow sorafenib tablets (e.g. any condition that impairs patient's ability to swallow pills)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with any evidence of a bleeding diathesis
  • Patients actively receiving anticoagulation with therapeutic intent; prophylactic anticoagulation (i.e. low dose warfarin) or venous or arterial access devices is allowed provided that the prothrombin time (PT), international normalized ratio (INR) or partial thromboplastin time (PTT) are normal
  • Pregnant women or women who are breast-feeding are excluded from this study because sorafenib (BAY 43-9006) is an investigational agent and teratogenicity has not been evaluated yet; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sorafenib (BAY 43-9006), breastfeeding should be discontinued if the mother is treated with sorafenib (BAY 43-9006)
  • Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with sorafenib (BAY 43-9006); patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy
  • Patients taking the cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin or St. John's wort due to potential drug interactions with sorafenib

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00390325


Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Bhavana Konda Ohio State University Comprehensive Cancer Center
  Study Documents (Full-Text)

Documents provided by National Cancer Institute (NCI):

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00390325     History of Changes
Obsolete Identifiers: NCT01645631
Other Study ID Numbers: NCI-2009-00196
NCI-2009-00196 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2006C0050
NCI-7609
CDR0000507441
OSU 06054 / IRB 2006C0050
7609 ( Other Identifier: Ohio State University Comprehensive Cancer Center )
7609 ( Other Identifier: CTEP )
N01CM00070 ( U.S. NIH Grant/Contract )
N01CM62207 ( U.S. NIH Grant/Contract )
P30CA016058 ( U.S. NIH Grant/Contract )
First Posted: October 19, 2006    Key Record Dates
Results First Posted: December 21, 2018
Last Update Posted: November 26, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Medullary
Carcinoma, Neuroendocrine
Neoplasms, Ductal, Lobular, and Medullary
Thyroid Neoplasms
Endocrine Gland Neoplasms
Multiple Endocrine Neoplasia
Multiple Endocrine Neoplasia Type 2a
Multiple Endocrine Neoplasia Type 2b
Thyroid Diseases
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine System Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Adenocarcinoma
Neoplasms, Nerve Tissue
Neoplasms by Site
Head and Neck Neoplasms
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
Sorafenib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action